Evotec AG (NASDAQ:EVO) Short Interest Down 79.0% in April

Evotec AG (NASDAQ:EVO) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 86,146 shares, a decline of 79.0% from the April 15th total of 409,474 shares. Based on an average daily volume of 131,198 shares, the short-interest ratio is presently 0.7 days. Approximately 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EVO shares. Wall Street Zen cut Evotec from a “hold” rating to a “sell” rating in a research report on Saturday. Berenberg Bank started coverage on Evotec in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, HC Wainwright started coverage on Evotec in a research report on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Apollon Wealth Management LLC acquired a new stake in Evotec in the 1st quarter valued at $28,000. BNP Paribas Financial Markets increased its holdings in Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares in the last quarter. Bank of America Corp DE increased its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. Marshall Wace LLP acquired a new stake in Evotec in the 4th quarter valued at $40,000. Finally, Thrivent Financial for Lutherans acquired a new stake in Evotec in the 3rd quarter valued at $53,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Trading Down 9.7%

Shares of NASDAQ:EVO traded down $0.29 during trading on Wednesday, hitting $2.71. 141,141 shares of the stock were exchanged, compared to its average volume of 111,648. The company has a fifty day moving average price of $2.81 and a two-hundred day moving average price of $3.18. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. Evotec has a 12-month low of $2.31 and a 12-month high of $4.80.

Evotec (NASDAQ:EVO) last posted its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.The firm had revenue of $297.02 million for the quarter. On average, research analysts expect that Evotec will post -0.63 EPS for the current fiscal year.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.